HIGHLIGHTS
- who: Josephine Louella Feliciano from the AOPapardo, Italy University of Naples Federico II, Italy have published the paper: Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer, in the Journal: (JOURNAL)
- what: The aim of this study was to estimate the adjusted OS treatment effect in EMPOWER-Lung 1 by accounting for confounding associated with patients who crossed over from chemotherapy to cemiplimab per the study design, and who received cemiplimab continuation with the addition of chemotherapy per . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.